Medical Doctor Program year 2020 Reported 2019–2020 Source: CMS Open Payments, 2026 publication

Paul Chretien

Neurodevelopmental Disabilities Sacramento, CA Medical Doctor

NPI 1972615227 CMS profile 89217

1111 Exposition Blvd., Bldg 700, Ste 102, Sacramento, CA 95815

Open in the dashboard

General payments

$3,791

181 records reported · program years 2019–2020

Research payments

$0

Paid to them · None reported · program years 2019–2020

Ownership & investment interest

$0

None reported

Through program year 2020, Paul Chretien of Sacramento, CA is reported in the CMS Open Payments database as having received $3,791 across 181 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 79th percentile of Neurodevelopmental Disabilities profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

2 rows
Year Kind Relative to this record's peak year Amount Records
2020 General $111 5
2019 General $3,681 176

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Paul Chretien
  • Neurodevelopmental Disabilities median
  • Middle half of Neurodevelopmental Disabilities
  • National median

In program year 2025, general payments to Paul Chretien were reported at $0. Among 64 Neurodevelopmental Disabilities profiles paid that year, the median was $136 and the middle half received between $67 and $819.

Show as a table
Year Paul Chretien Neurodevelopmental Disabilities median Middle half National median
2019 $3,681 $138 $34–$757 $163
2020 $111 $63 $23–$471 $114
2021 $0 $158 $43–$1,017 $132
2022 $0 $225 $76–$1,106 $149
2023 $0 $228 $73–$994 $160
2024 $0 $167 $57–$1,310 $164
2025 $0 $136 $67–$819 $169

Breakdown

Who paid General payments · program years 2019–2020
  1. Tris Pharma Inc $1,197 17 payments
  2. UCB, Inc. $533 26 payments
  3. Novartis Pharmaceuticals Corporation $389 13 payments
  4. Supernus Pharmaceuticals, Inc. $305 22 payments
  5. Greenwich Biosciences, Inc. $300 13 payments
  6. Sunovion Pharmaceuticals Inc. $233 41 payments
  7. Neos Therapeutics, LP $173 12 payments
  8. Ironshore Pharmaceuticals Inc. $130 9 payments
  9. LivaNova USA, Inc. $79 4 payments
  10. Eisai Inc. $78 5 payments
  11. Other $373 19 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2020
  1. Food and Beverage $3,791 181 payments
Products named General payments · program years 2019–2020
  1. Quillivant XR $658 10 payments
  2. Dyanavel XR $540 7 payments
  3. Briviact $502 23 payments
  4. Epidiolex $300 13 payments
  5. APTIOM $233 41 payments
  6. AFINITOR $219 7 payments
  7. TROKENDI XR $178 12 payments
  8. Adzenys XR-ODT $173 12 payments
  9. COTEMPLA XR-ODT $173 12 payments
  10. GILENYA $170 6 payments
  11. Other $853 52 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

181 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurodevelopmental Disabilities in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2020

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record